24 June 2020 Image: Sincerely Media Applied Photophysics (APP) and Fluorescence Innovations (FI) have entered into a joint venture agreement to develop and produce protein stability systems for leading researchers and industries around the globe. The two firms said they will be equal partners in the new initiative. Read More
22 June 2020 SLAS Transformed is an interactive event focused on omics, synthetic biology and genome editing along with applicable implications for the current pandemic. The two-day event runs from 23-24 June 2020, offering 30-minute scientific research presentations, live exhibitor presentations and one-on-one networking sessions. It will span multiple… Read More
Novasep, viral vector producer, has signed a partnership with AstraZeneca for the production of the Oxford University COVID-19 vaccine. Novasep will produce the active substance of the vaccine in its Belgian facilities The partnership follows the agreement between AstraZeneca and the Inclusive Alliance for Vaccines (IAV), to supply… Read More
16 June, 2020 The global science-led biopharmaceutical company said the detailed results from both the Phase II ACE-CL-001 trial and the pivotal Phase III ASCEND trial showed the long-term efficacy and tolerability of Calquence (acalabrutinib) in chronic lymphocytic leukaemia (CLL), one of the most common types of adult… Read More
11 June, 2020 The British-Swedish multinational is to present new data from the landmark Phase III DAPA-HF and DECLARE-TIMI 58 trials at the upcoming 80th American Diabetes Association (ADA) Virtual Scientific Sessions, taking place June 12-26. According to AstraZeneca, the data to be presented is among 23 accepted… Read More
21 May, 2020 A study by Faron Pharmaceuticals Oy has shown that the desired mechanism of action of IV IFN beta-1a in the lung vasculature, the upregulation of CD73, is blocked by the administration of glucocorticoids. Faron Pharmaceuticals Oy, a clinical stage biopharmaceutical company, has announced the results… Read More
The CRISPR revolution arrives in immuno-oncology By Helen Stewart-Miller and Thomas Hope Volume 21 Issue 2 – Spring 2020 CRISPR-cas9 technology is having an exciting impact on drug discovery as a whole, but more specifically CRISPR presents enormous opportunities in targeted screening for immuno-oncology research. Clustered… Read More
Meeting analytical challenges in a brave new world of next generation biotherapeutics By Mani Krishnan and Susan Darling Volume 21 Issue 2 – Spring 2020 The need for innovative advanced analytical tools to accelerate the development of immunotherapies and other complex biologics that may one day cure genetic… Read More
Innovative glycan imaging methods drive cancer biomarker discovery By Dr Richard Drake, Dr Anand Mehta and Dr Peggy Angel Volume 21 Issue 2 – Spring 2020 Glycosylation accounts for the majority of post-translational modifications (PTMs) of proteins, and changes in glycosylation are known to play a key role… Read More
By Andrii Lozoniuk Volume 21 Issue 2 – Spring 2020 Gathering compound solubility data is a key step during drug discovery that helps ensure cost-effective screening, yet it is a long process and is often underestimated in terms of difficulty. Global sharing of such data can… Read More
Target discovery and drug development what comes after CRISPR? By Benedict CS Cross Volume 21 Issue 2 – Spring 2020 For an area of research as important and impactful as drug discovery, it is surprising how often efforts in this field are directed by short-term trends. We have… Read More
Reprogramming the stem cell for a new generation of cures By Dr Alex Davenport, Dr Tonya Frolov and Dr Mark Kotter Volume 21 Issue 2 – Spring 2020 The development of new and effective treatments with the potential to cure, or at the very least ease patient suffering,… Read More
Cryo-EM accelerates drug discovery by delivering previously intractable structural insights By Hans Raaijmakers, et al. Cryo-electron microscopy (cryo-EM), a powerful biophysical technique that can analyse molecular assemblies, is changing the paradigm in structure-based drug design. As targets become more challenging, solving structures of drug target molecules… Read More
Harnessing the modified proteome for increased diagnostic power By Dr David Bramwell, Dr Steven Laval and Dr Jane McLeod Relevant biomarkers are vitally important in personalised medicine, guiding patient matching to specific therapies for earlier, easier and more effective disease identification and treatment. Here we trace… Read More
Getting a handle on liquids: automation solutions for drug discovery By Helen Stewart-Miller and Thomas Hope The accurate and precise measurement of liquids and the transport of exact volumes between vessels, or from one instrument to another, are processes that constitute the very essence of research. Read More
Unlocking the potential of Extracellular Vesicles: from single molecules to novel therapeutics By Dr Anna Caballe and Dr Katarzyna Ginda-Makela As part of normal homeostasis, cells release different types of small-sized membrane vesicles to traffic analytes across membranes, communicate with other cells and remove unwanted cell content. These… Read More